IHI: Pullback Creates A Buying Opportunity In High-Growth MedTech

Wilson Research512 FollowersFollow5ShareSavePlay(13min)CommentsSummaryI rate iShares US Medical Devices ETF a buy, as its recent selloff offers an attractive entry into industry-leading medical device innovators.IHI's top holdings—Abbott Laboratories, Intuitive Surgical, and Boston Scientific—drive growth through strong fundamentals, product innovation, and exposure to secular healthcare trends.Despite higher fees (0.38%) and volatility, IHI's concentrated exposure to medical devices positions it for long-term capital appreciation over more diversified healthcare ETFs.Risks include economic sensitivity, concentration in top holdings, and high valuation multiples, but structural demand from aging populations and chronic conditions supports the investment case.PhonlamaiPhoto/iStock via Getty Images Investment Thesis iShares US Medical Devices ETF (IHI) warrants a Buy rating due to its selloff driven by short-term concerns and the innovative growth potential of its top holdings. Specifically, IHI's top holdings are industry leaders inThis article was written byWilson Research512 FollowersFollowWilson Research seeks to provide investors with focused insights on predominantly exchange-traded funds, or ETFs, with a blend between growth potential and dividend yield. The analysis provided emphasizes fundamental analysis while including macro-level factors such as industry trends, economics, geopolitics, and a variety of other influential factors. Wilson Reseach includes an MBA graduate and independent financial coach who seek to provide actionable information for long-term investors who value diversification while keeping their fees as low as possible. Wilson Research is inspired by the investment philosophies of Warren Buffett and the entrepreneurial philosophies of Robert Kiyosaki.Analyst’s Disclosure: I/we have a beneficial long position in the shares of UNH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is exclusive to Seeking Alpha. No duplication or reproduction of this article is allowed without consent of Seeking Alpha and the author. This article should not be misconstrued as individual financial advice. Always conduct your own due diligence prior to investing.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.